India pharma #crm #pharma


Posted On Apr 22 2017 by

#india pharma

#

AstraZeneca Pharma India Limited (AZPIL) has interests in seven crucial areas of healthcare:

• Brilinta® (Ticagrelor Tablets 90mg)

• Betaloc® (Metoprolol Tartrate Tablets IP 25mg, 50mg 100mg)

• Seloken XL® (Metoprolol Succinate Extended Release Tablets USP 25mg, 50mg 100mg)

• Imdur® (Prolonged Release Isosorbide-5-Mononitrate Tablets BP 30mg 60mg)

• Crestor® (Rosuvastatin Tablets IP 5mg, 10mg, 20mg 40mg)

• Seloram™ (Metoprolol Succinate Extended Release Ramipril Tablets 25/2.5mg, 25/5mg 50/5mg)

• Vigocil® (Voglibose Orally Disintegrating Tablets 0.2mg 0.3mg)

• Vigocil M® (Voglibose and Metformin Hydrochloride Tablets 0.2/500mg 0.3/500mg)

• Nitract SR™ (Nitroglycerin Sustained Release Capsules 2.5mg 6.5mg)

• Valfect™ (Valsartan Tablets 40mg, 80mg 160mg)

• Olways™ (Olmesartan Medoxomil Tablets 20mg 40mg)

• Olways H™ (Olmesartan Medoxomil and Hydrochlorothiazide Tablets 20/12.5mg 40/12.5mg)

• Olways AM™ (Olmesartan Medoxomil and Amlodipine Besilate Tablets 20/5mg)

• Onglyza® (Saxagliptin Tablets 2.5mg)

• Kombiglyze XR™ (Saxagliptin Metformin HCl Extended Release Tablets 2.5/1000mg 5/500mg)

• Byetta™ (Exenatide Injection 250 mcg/mL, 1.2mL 2.4mL prefilled pen]

• Mit’s Linctus Codeinae Co® (Codeine Phosphate and Chlorpheniramine Maleate Syrup)

• Mit’s Linctus DX™ (Dextromethorphan Hydrobromide, Phenylephrine Hydrochloride and Chlorpheniramine Maleate Syrup)

• Bricarex® (Terbutaline Sulphate and Guaiphenesin Syrup)

• Bricarex A® (Ambroxol, Terbutaline Sulphate and Guaiphenesin Expectorant)

• Bricacef™ (Cefpodoxime Proxetil and Potassium Clavulanate Tablets 200/125mg)

• Bricacef DT™ (Cefpodoxime Proxetil and Clavulanate Potassium Dispersible Tablets 100/62.5mg)

• Bricacef PED® (Cefpodoxime Proxetil and Clavulanate Potassium for Oral Suspension 50/31.25mg)

• Bricanyl Syrup® (Terbutaline Sulphate Syrup)

• Symbicort® (Budesonide/Formoterol Inhalation Powder 160/4.5mcg/dose)

• Prostodin® (Carboprost Tromethamine Injection IP 125mcg 250mcg)

• Cerviprime® (Dinoprostone Gel)

• Partocin™ (Oxytocin Injection 5IU)

• Arimidex® (Anastrozole Tablets IP 1mg)

• Nolvadex™ (Tamoxifen Tablets IP 10mg)

• Iressa® (Gefitinib Tablets IP 250mg)

• Zoladex® (Goserelin Acetate Injection 3.6mg Goserelin Acetate Depot Injection 10.8mg)

• Casodex® (Bicalutamide Tablets USP 50mg)

• Faslodex™ (Fulvestrant Injection 250mg)

• Meronem® (Meropenem Injection IP 500mg 1g)

• Vancocin CP® (Vancomycin Hydrochloride for Intravenous Infusion IP 500mg)

• Enclere® (Cefoperazone and Sulbactam for Injection 500/500mg 1000/1000mg)

• Enclere Forte® (Cefoperazone and Sulbactam for Injection 1000/500mg 2000/1000mg)

• Remergin™ (Colistimethate Sodium for Injection BP 1MIU)]

• Xylocaine® (Lignocaine Hydrochloride Injection IP 2%)

• Xylocaine Viscous® (Lidocaine Hydrochloride Oral Topical Solution USP)

• Sensorcaine® (Bupivacaine Injection IP 0.25% 0.5%)

• Sensorcaine Heavy® (Bupivacaine Hydrochloride in Dextrose Injection USP)

• Diprivan® (Propofol 1%W/V Injection)

• Naropin® (Ropivacaine Hydrochloride Injection USP 0.2% 0.75%)

• Neksium Tablets™ (Esomeprazole Tablets 20mg 40mg)

• Neksium Injection® (Esomeprazole Sodium Powder for Solution for Injection 40mg)

*In alliance with Bristol Myers Squibb

Adverse event reporting

All pharmacologically effective drugs have benefits and risks. The risk may be insignificant or may be acceptable in relation to the drug’s therapeutic action. Continuous monitoring of the safety of a drug throughout the duration of its use helps to ensure that its risks and benefits remain acceptable. AstraZeneca is committed to protecting the safety of patients who receive our products.

Report any suspected Adverse Events to AstraZeneca medications through the established procedures.

Why report Adverse Event?

  • Adverse Event reporting helps AstraZeneca to identify rare and very rare adverse effects
  • Reporting leads to regular review of safety database for new risks or signals.
  • Adverse Event reports help to provide current and accurate updates on safety profiles of the drugs
  • Adverse Event reports help to identify different profiles of known adverse reactions with regards to severity, nature or outcome

What is an adverse event?

An Adverse Event is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product.

You may be more familiar with the tern “side effect”

What does this include?

Adverse Event includes undesirable medical condition that can be symptoms (for example nausea, chest pain), signs (for example tachycardia, enlarged liver) or the abnormal results of an investigation (for example laboratory findings, electrocardiogram). Adverse Events are not necessarily caused by the medication – the event just needs to have occurred after taking a medicine and AstraZeneca also collects the reports of :

  • Drug exposure during pregnancy and breastfeeding
  • Lack of drug effect
  • Drug overdose or medication error
  • Drug abuse or misuse
  • Transmission of infectious agents via an AstraZeneca product
  • Drug Interactions

1. Patient identifier

• Who experienced the Adverse Event?

• Patient and reporter identifier is important to avoid case duplication and facilitate follow up of appropriate cases

• The term identifiable in this context refers to the verification of the existence of a patient (e.g. you might provide: sex, age etc)

2. Event description

• What was the Adverse Event?

• Describe the nature of the adverse event, any signs and symptoms and outcome of the event

• Who is reporting the Event?

• Give your name, address and phone number as you may need to be contacted for further information

• If you are reporting on behalf of a healthcare professional (e.g. if you are a sales representative), be prepared to also give their details.

• What AstraZeneca product was taken by the patient?

• Provide the name of the AstraZeneca product taken by the patient

If you do not have all the details listed above. please still report the Adverse Event. In addition, you can report any other details you have about the Adverse Event.

Report the Adverse Event even if you don’t think it is serious, relevant or caused by AstraZeneca product.

You can report the Adverse Event by using the Adverse Event Report Form. (Insert docs)

Contact AstraZeneca Patient Safety at

Tel: +91-80-67748000 (Ext. 8458)

CSR

Please click here to read more about the CSR Policy (PDF 87kb)

2. Young Health Programme

Young Health Programme is AstraZeneca’s global community investment programme and is designed to help young people in need around the world deal with the health issues they face and improve their chances for a better life in the future.

In India, YHP was started in November 2010. The programme is initiated in five resettlement colonies around New Delhi. The focus area of the programme includes addressing health issues related to Sexual and Reproductive Health, TB, Dengue, Malaria, Substance Abuse and Life Style diseases.

YHP India has directly been able to reach out to 89,493 young people (40,271 boys and 49,222 girls), and has influenced 84,387 wider community members, including health professionals, educators and policy makers. The YHP trained an additional 818 adolescents as Peer Educators during the second year of operations. The establishment of 15 Health Information Centres (HICs) which act as a forum for the youth. The second vital approach is the training and support of 1,581 Peer Educators (of which 814 are girls, who are actively responsible for delivering health messages to other youngsters in school and communities. YHP India continues to enhance knowledge on health issues and ways to cope with it for adolescents and hopes to reach a larger audience as the year’s progress.

Please click here to read more about the Young Health Programme

Investor Relations

You are now leaving AstraZeneca.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.

Important notice for users

You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.





Last Updated on: April 21st, 2017 at 10:21 pm, by


Written by admin


Leave a Reply

Your email address will not be published. Required fields are marked *